Icon signals $8B full-year revenue midpoint as metabolic and obesity trial momentum builds Jul. 24, 2025 6:22 PM ET ICON Public Limited Company (ICLR) Stock AI-Generated Earnings Calls Insights ...

Microsoft reports that annual revenue for its Azure cloud platform has risen 34% to $75 billion. The Azure business is central to Microsoft's shift towards artificial intelligence. On Wednesday, ...

NIESR nudged up its forecast for British economic growth for this year to 1.3% from its forecast of 1.2% made in May. But it ...

Maharashtra Revenue Department has mandated the use of Face App and geo-fencing systems for all its employees. The plan, in line with a central directive, is meant to ensure that attendance is ...

Investing.com - ICON PLC (NASDAQ: ICLR) reported second quarter EPS of $3.26, $0.07 better than the analyst estimate of $3.19. Revenue for the quarter came in at $2.02B versus the consensus estimate ...

Investing.com - ICON PLC (NASDAQ: ICLR) reported second quarter EPS of $3.26, $0.07 better than the analyst estimate of $3.19. Revenue for the quarter came in at $2.02B versus the consensus ...

For the current quarter ending in September, FormFactor expects its per-share earnings to range from 21 cents to 29 cents. The company said it expects revenue in the range of $195 million to $205 ...

Efforts by Trump and Mexico don’t address root causes or measure up to an evolving, international fentanyl market, experts ...

Other desirable serial numbers include repeating patterns like '123456' or '11 11 11 11', palindromic numbers eg '2002' and numbers with historical significance such as his birthday.

NXP's revenue for the second quarter fell 6.4% to $2.93 billion, although it still narrowly beat analyst expectations of $2.90 billion, according to data compiled by LSEG.

Netflix beats analyst estimates for revenue and earnings per share in the second quarter. A look at the key highlights.

Final Takeaway ICON management emphasized progress in Q2 2025 with stronger gross bookings, revenue ahead of expectations, and expanded partnerships in biotech and metabolic disease trials.